Article Text
Abstract
Objectives: Several studies suggested chromosome 12 harbours an Alzheimer’s disease (AD) risk factor gene. Significant association of a single nucleotide polymorphism (SNP) in the 3′ UTR of transcription factor CP2 (LBP-1c/CP2/LSF or TFCP2) at 12q13 was reported in three independent case-control studies, but no family based analyses have been performed to date.
Methods: Genotypes for three SNPs were generated in two independent AD family samples. A meta-analysis on all published case-control studies was also performed.
Results: The A allele of the 3′ UTR SNP was associated with increased risk for AD in one sample (odds ratio (OR) 2.1, 95% confidence interval (95% CI) 1.1 to 4.3), but not in the other, possibly due to low power. Haplotype analyses showed that this allele is part of a putative risk-haplotype overtransmitted to affected individuals in one sample and in both samples combined. Meta-analysis of the previously associated 3′ UTR SNP showed a trend towards a protective effect of the A allele in AD (OR 0.73, 95% CI 0.5 to 1.1).
Conclusions: This is the first study to examine LBP-1c/CP2/LSF in AD families, and the fifth to independently show significant association. While our results support a role of this gene in AD pathogenesis, the direction of the effect remains uncertain, possibly indicating linkage disequilibrium with another variant nearby.
- AD, Alzheimer’s disease
- CAG, Consortium on Alzheimer’s Genetics
- CLR, conditional logistic regression
- LD, linkage disequilibrium
- OR, odds ratio
- PDT, pedigree disequilibrium test
- SNP, single nucleotide polymorphism
- 95% CI, 95% confidence interval
- CP2
- family based association
- FBAT
- LBP-1c
- LSF
- TFCP2
- transcription factor CP2
Statistics from Altmetric.com
Footnotes
-
This work was sponsored by grants from the NIMH, the NIA (ADRC), and the Alzheimer Association. LB was a fellow of the Deutsche Forschungsgemeinschaft (DFG) and now receives a fellowship from the Harvard Center for Neurodegeneration and Repair (HCNR), Core A, and a stipend from the National Alliance for Research on Schizophrenia and Depression (NARSAD). MBM is supported by a National Research Service Award, Training Program in Psychiatric Epidemiology and Biostatistics (T32 MH17119).
-
Competing interests: none declared